Abstract
A 300-fold adriamycin resistant variant (DLKP-A) of the human lung squamous cell carcinoma line DLKP was established by stepwise selection in increasing concentrations of adriamycin. Different levels of cross-resistance were observed towards VP-16, VM-26, colchicine, vincristine and, somewhat unexpectedly, cis-platin. Resistance was stable for at least 3 months in culture in the absence of drug. P-glycoprotein overexpression was detected by immunofluorescence and Western Blotting, and a direct causal role for P-glycoprotein overexpression in the resistant phenotype was established by transfection with an mdr1 specific antisense oligonucleotide. A modified cryopreservation procedure was necessary for the resistant variant line. The resistant population displays clonal heterogeneity with respect to resistance level. A higher frequency of double minute chromosomes was observed in DLKP-A when compared with the parental cell line.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ADR:
-
adriamycin
- COLH:
-
colchicine
- C-PT:
-
cis-platin
- MDR:
-
multidrug resistance
- NSCLC:
-
non-small cell lung carcinoma
- VCR:
-
vincristine
- VP-16:
-
etoposide
- VM-26:
-
tenoposide
References
Baas, F, Jongsma, A, Broxterman, H, Arceci, R, Housman, D, Scheffer, G, Riethorst, A, Van Groenigen, M, Nieuwint, A and Joense, H (1990) Non P-glycoprotein mediated mechanism for MDR precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in human cancer cell line. Cancer Res 50: 5392–5398.
Beck, WT (1989) Unknotting the complexities of MDR; the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 81: 1683–1686.
Bradley, G, Juranka, P and Ling, V (1988) Mechanisms of multidrug resistance. Biochim Biophys Acta 948: 87–128.
Citro, G, Cucco, C, Verdina, A and Zupi, G (1991) Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64: 534–536.
Clynes, M, Redmond, A and Heenan, M (1990) Review: Recent developments in research on Multidrug Resistance in cancer cells. Cancer J 3: 34–39.
Cole, SP, Downes, HP, Mirski, S and Clements, J (1990) Alterations in glutathione and glutathione related enzymes in a multidrug-resistant small cell lung cancer cell line. Mol Pharmacol 37: 192–197.
Coley, HM, Workman, P and Twentyman, P (1991) Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer 63: 351–357.
Dalton, WS and Grogan, TM (1991) Does P-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it? J Natl Cancer Inst 83: 80–81.
de Jong, C, Zijlstra, J, de Vries, E and Mulder, N (1990) Reduced DNA Topoisomerase 11 activity and drug-mediated DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304–309.
Ford, JM and Hait, WN (1990) Pharmacology of drugs that alter Multidrug Resistance in cancer. Pharmacol Rev 42: 155–199.
Georges, E, Bradley, G, Gariepy, J and Ling, V (1990) Detection of P-glycoprotein by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 87: 152–156.
Gottesman, M, Willingham, MC, Thiebaut, T and Pastan, I (1991) Expression of the mdr1 gene in normal human tissues. In: Ronninson, I (ed.) “Molecular and Cellular Biology of Multidrug Resistance in tumor cells“ Plenum Press, New York, pp. 279–290.
Higgins, CF and Gottesman, MM (1992) Is the multidrug transporter a flippase? Trends Biochem Sci 17: 18–21.
Johnson, GD, Davidson, RS, McNamee, KC, Goodwin, RD and Holborow, EJ (1982) Fading of immunofluorescence during microscopy: A study of the phenomen and its remedy. J Immunolog Meth 55: 231–242.
Kasahara, K, Fujiwara, Y, Sugimoto, Y, Nishio, K, Tamura, T, Matsuda, T and Saijo, N (1992) Determinants of response to the DNA Topoisomerases 11 inhibitors Doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84: 113–118.
Laemmli, EK (1970) Clevage of structural proteins during the assembly of bacteriophage T4. Nature 227: 680–695.
Lai, SL, Goldstein, LH, Gottesman, M, Pastan, I, Tsai, C, Johnson, B, Mulshine, J, Ihde, C, Kavser, K and Gazdar, A (1989) MDR1 expression in Lung Cancer. J Natl Cancer Inst 81: 1144–1150.
Law, E, Gilvarry, V, Grant, G, Gregory, B and Clynes, M (1992) Cytogenetic comparison of two poorly differentiated human lung squamous cell carcinoma cell lines. Cancer Genet Cytogenet 59: 111–118.
Long, B, Wang, L, Lorico, A, Wang, R, Brattain, M and Casazza, A (1991) Mechanisms of resistance to etoposide and tenoposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res 51: 5275–5284.
Martin, A and Clynes, M (1991) Acid-phosphatase endpoint for in vitro toxicity tests. In Vitro Dev Biol 27A: 183–184.
Moscow, JA, Fairchild, CR, Madden, MJ, Ransom, DT, Wieand, HS, O'Brien, EE, Poplack, DG, Cossman, J, Myers, CE and Cowan, KH (1989) Expression of anionic Glutathione-S-Transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49: 1422–1428.
Redmond, A, Law, E, Gilvarry, U and Clynes, M (1990) Establishment of two multidrug resistant variants of the human tumor cell line Hep-2. Cell Biol Toxicol 6: 293–302.
Richert, ND, Aldwin, L, Nitecki, D, Gottesman, MM and Pastan, I (1988) Stability and covalent modification of P-glycoprotein in multidrug resistant KB cells. Biochemistry 27: 7607–7613.
Rivoltini, L, Colombo, MP, Supino, R, Ballainari, D, Tsuruo, T and Parianti, G (1990) Modulation of multidrug resistance by verapamil or MDR1 antisense oligonucleotides does not change the high susceptibility to lymphokine-activated killers in MDR activiated carcinomas (Lovo) line. Int J Cancer 46: 727–732.
Ronchi, E, Sanfilippo, O, di Fronzo, G, Bani, MR, Torre, P, Catania, S and Silvestrini, R (1989) Detection of P-170 glycoprotein in neoplastic and normal tissue. Tumori 75: 542–546.
Roninson, IB (1991) Molecular and Cellular biology of Multidrug resistance in tumor cells. Plenum Press, New York.
Seabright, M (1971) A rapid banding technique for banding human chromosomes. Lancet 2: 971–972.
Smith, PK, Krohn, RI, Hermanson, AK, Mallia, FH, Gartner, MD, Provenzano, EK, Fujimoto, NM, Goeke, NM, Olson, BJ and Klenk, DC (1985) Measurement of protein using bincinchoninic acid. Anal Biochem 150: 76–85.
Van der Valk, P, Van Kalken, C, Ketelaars, H, Broxterman, HJ, Scheffer, G, Kuiper, C, Tsuruo, T, Lankelma, J, Meijer, C, Pinedo, H and Scheper, R (1990) Distribution of multidrug associated P-glycoprotein in normal and neoplastic human tissue. Ann Oncol 1: 56–64.
Valverde, MA, Diaz, M, Sepulveda, FV, Gill, DR, Hyde, SC and Higgins, CF (1992) Volume regulated chloride channels associated with the human multidrug resistant P-glycoprotein. Nature 355: 830–833.
Versantvoort, C, Broxterman, H, Pinedo, H, de Vries, E, Fellor, N, Kuiper, C and Lankelma, J (1992) Energy dependent processes involved in reduced drug accumulation in multidrug resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res 52: 17–23.
Volm, M, Mattern, J and Samsel, B (1991) Overexpression of P-glycoprotein Glutathione-S-Transferase pi in resistant non-small cell lung carcinomas of smokers. Br J Cancer 64: 700–704.
Wilbur, DW, Camacho, ES, Hillard, DA, Dill, PL and Weisenthal, LM (1992) Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measures total tumor cell kill. Br J Cancer 65: 27–32.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clynes, M., Redmond, A., Moran, E. et al. Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A. Cytotechnology 10, 75–89 (1992). https://doi.org/10.1007/BF00376102
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00376102